Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Peroxide SCHEMBL5147765 | 0.97 | ALDH1A1 (0.38) | ALDH1A1TDP1MMP8CYP2C19GAA | |
| SCHEMBL11615295 | 0.81 | CYP1A2 (0.33) | ALDH1A1TDP1GAATSHR | |
| SCHEMBL19111943 | 0.81 | ALDH1A1 (0.32) | ALDH1A1TDP1GAA | |
| SCHEMBL18112355 | 0.80 | MMP8 (0.36) | ALDH1A1TDP1MMP8CYP2C19CA2 | |
| SCHEMBL10562537 | 0.79 | ALDH1A1 (0.31) | ALDH1A1TDP1GAA | |
| SCHEMBL17298363 | 0.79 | FDPS (0.41) | ALDH1A1TDP1GAATSHR | |
| SCHEMBL14215959 | 0.79 | ALDH1A1 (0.31) | ALDH1A1TDP1GAA | |
| SCHEMBL17298362 | 0.79 | FDPS (0.41) | ALDH1A1TDP1GAATSHR | |
| SCHEMBL12557328 | 0.79 | FDPS (0.41) | ALDH1A1TDP1GAATSHR | |
| SCHEMBL301722 | 0.78 | ACACB (0.40) | ALDH1A1TDP1MMP8CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0324554-B1 | IMPROVEMENTS IN RUBBER FOR MEDICAL OR PHARMACEUTICAL ARTICLES | DAIKYO GOMU SEIKO LTD. (JP) | 1992-11-11 | — | — | EP | claimed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-9718790-B2 | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same | SHIONOGI & CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| US-8637557-B2 | Aminothiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20130252883-A1 | Macrocycles and Their Uses | NOVARTIS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130172317-A1 | TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION HAVING AN ANALGESIC ACTIVITY COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8476224-B2 | Macrocycles and their uses | NOVARTIS AG (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| WO-2011023864-A1 | PSEUDODIPEPTIDES AS MMP INHIBITORS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2011-03-03 | — | — | WO | disclosed |
| EP-1231199-B1 | Process for the condensation of aldehydes with ketones by multiphase reaction | OXENO OLEFINCHEMIE GMBH (DE) | 2005-07-20 | — | — | EP | disclosed |
| JP-2005112774-A | METHOD FOR PRODUCING 3, 3, 5-TRIMETHYLCYCLOHEXANONE | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL & TECHNOLOGY | 2005-04-28 | — | — | JP | disclosed |
| US-6603047-B2 | Preparation of alpha,beta-unsaturated ketones by condensation of aldehydes with ketones | OXENO OLEFINCHEMIE GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| US-20020161264-A1 | Condensation of aldehydes with ketones by multiphase reaction | DE GUSSA AG (DE) | 2002-10-31 | — | — | US | disclosed |
| EP-1231199-A1 | Process for the condensation of aldehydes with ketones by multiphase reaction | Oxeno Olefinchemie GmbH (DE) | 2002-08-14 | — | — | EP | disclosed |
| EP-0680095-A2 | Light-transmissive resin sealed semiconductor | CANON KABUSHIKI KAISHA (JP) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | AKT3, AKT2, JAK1 | ALDH1A1 1711/4885TDP1 2348/4885MMP8 1228/4885 |
| US-20130252883-A1 | Macrocycles and Their Uses | MRPL21, CLPP, MLEC | ALDH1A1 3067/4885TDP1 4364/4885MMP8 18/4885 |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | ALDH1A1 3298/4885TDP1 678/4885MMP8 1566/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 2338/4885TDP1 4535/4885MMP8 1030/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ALDH1A1 2338/4885TDP1 4535/4885MMP8 1030/4885 |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | ALDH1A1 1602/4885TDP1 2890/4885MMP8 1164/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | ALDH1A1 353/4885TDP1 1091/4885MMP8 452/4885 |
| US-20130172317-A1 | TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION HAVING AN ANALGESIC ACTIVITY COMPRISING THE SAME | P2RX3, P2RX4, P2RX2 | ALDH1A1 2167/4885TDP1 3549/4885MMP8 3689/4885 |
| US-20020161264-A1 | Condensation of aldehydes with ketones by multiphase reaction | COASY, ACACB, ACACA | ALDH1A1 61/4885TDP1 3732/4885MMP8 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.